Drugs / DI-B4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01805375 | Apr 2013 → Dec 2017 | B-cell chronic lymphocytic leukemia, Waldenstrom macroglobulinemia | Cancer Research UK | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DI-B4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01805375 ↗ |
| Action | Deplete | “DI-B4 is expected to act through the depletion of normal and malignant CD19 positive cells, primarily via ADCC.” NCT01805375 ↗ |
| Modality | Monoclonal antibody | “DI-B4 is a type of drug called an Anti-CD19 monoclonal antibody” NCT01805375 ↗ |
| Route | Intravenous | “DI-B4 will be given weekly by intravenous infusion for four weeks.” NCT01805375 ↗ |
| Target | CD19 | “The target antigen, CD19, is the canonical B-cell marker” NCT01805375 ↗ |